• Poster presentation highlights  Phase 1 data showing VMX-C001 has no effect on the anticoagulant function of heparin in healthy subjects

Leiden, The Netherlands, 1 December 2025 – VarmX, a biotech company developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and treatment of inherited coagulation disorders, will be presenting Phase 1 clinical data on lead asset, VMX-C001 in a poster presentation at the 67th ASH Annual Meeting and Exposition in Orlando, Florida from 6-9 December 2025.

VarmX’s CMO, Dr Ged Short, will present the poster VMX-C001 has no effect on the anticoagulant function of heparin in healthy subjects on 8 December at from 6pm at the Orange County Convention Center, West Halls B3-B4, as part of Session 321, Coagulation and Fibrinolysis: Basic and Translational.

The poster presentation highlights the findings from the Phase 1 single site, open-label study of VMX-C001 in healthy subjects, demonstrating that VMX-C001 with or without a FXa DOAC did not impact the anticoagulant activity of Unfractionated heparin (UFH) or Low Molecular Weight Heparin (LMWH).

Thus, VMX-C001 can restore coagulation in people taking FXa DOACs, without affecting UFH administered immediately after VMX-C001 for anticoagulation during vascular surgery or for cardiopulmonary bypass and LMWH can be used as thromboprophylaxis or anticoagulation in individuals administered VMX-C001.

The abstract for the poster presentation can be found here: https://meetings-api.hematology.org/api/abstract/vmpreview/290515.